Trials / Completed
CompletedNCT06561841
A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
A Multicenter, Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open-label phase 2 study. Adult Patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. Subjects were treated with HSK39297 for 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK39297 | HSK39297 tablets for 24 weeks |
Timeline
- Start date
- 2024-07-17
- Primary completion
- 2025-04-02
- Completion
- 2025-04-02
- First posted
- 2024-08-20
- Last updated
- 2025-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06561841. Inclusion in this directory is not an endorsement.